<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
In an overvalued market – AbbVie offers growing dividends for dividend-seeking investors, and it’s still undervalued for value investors seeking value upside. AbbVie generates ample free cash to cover their debt, and they are ready to offset Humira’s decline in 2023.
...read full article on Seeking Alpha
